{
  "extraction_metadata": {
    "timestamp": "2025-09-05T10:14:21.404403",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 3,
    "total_picos": 19
  },
  "picos_by_country": {
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "progression-free survival (PFS; e.g., median 5.6 months [95% CI: 4.3; 7.8] in CodeBreaK 200, median 6.7 months [95% CI: 4.6; 8.3] in Awad 2022, with subgroup data for ECOG status), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including functional and symptom scales), time to deterioration in quality of life (EORTC QLQ-C30 and QLQ-LC13), adverse events (AEs; including frequency and severity, e.g., ≥ grade 3 AEs, treatment-related AEs, serious adverse events [SAEs], discontinuations due to AEs, specific AEs such as diarrhoea, increased ALT/AST, anaemia, fatigue, constipation, neutropenia, fever, etc.), treatment-related adverse events leading to discontinuation, treatment-related adverse events resulting in death, incremental cost-utility ratio (ICUR) from the public payer perspective, cost-utility analysis (CUA), budget impact analysis, and utility outcomes."
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10268
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life, adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life, adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life, adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life, adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life, adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life, adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life, adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours and except in cases of predominantly squamous histology",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life, adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life, adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours and adenocarcinoma histology",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life, adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10591
    },
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "objective response rate (ORR; primary endpoint; measured by RECIST v1.1), duration of response (DoR), disease control rate, progression-free survival (PFS; including median PFS, hazard ratio for progression or death, and 12-month PFS rate), overall survival (OS; including median OS, hazard ratio for death, and 12-month OS rate), time to progression, time to next treatment, event-free survival, duration of treatment, time to deterioration of overall health status (including hazard ratio and mean change from baseline to week 12), time to deterioration of physical functioning, quality of life (overall health status; measured by change from baseline and time to deterioration), adverse event rate (measured by CTCAE v5), rate of grade 3-4 adverse events, discontinuations due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel + nintedanib",
          "Outcomes": "objective response rate (ORR; primary endpoint; measured by RECIST v1.1), duration of response (DoR), disease control rate, progression-free survival (PFS; including median PFS, hazard ratio for progression or death, and 12-month PFS rate), overall survival (OS; including median OS, hazard ratio for death, and 12-month OS rate), time to progression, time to next treatment, event-free survival, duration of treatment, time to deterioration of overall health status (including hazard ratio and mean change from baseline to week 12), time to deterioration of physical functioning, quality of life (overall health status; measured by change from baseline and time to deterioration), adverse event rate (measured by CTCAE v5), rate of grade 3-4 adverse events, discontinuations due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "objective response rate (ORR; primary endpoint; measured by RECIST v1.1), duration of response (DoR), disease control rate, progression-free survival (PFS; including median PFS, hazard ratio for progression or death, and 12-month PFS rate), overall survival (OS; including median OS, hazard ratio for death, and 12-month OS rate), time to progression, time to next treatment, event-free survival, duration of treatment, time to deterioration of overall health status (including hazard ratio and mean change from baseline to week 12), time to deterioration of physical functioning, quality of life (overall health status; measured by change from baseline and time to deterioration), adverse event rate (measured by CTCAE v5), rate of grade 3-4 adverse events, discontinuations due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "objective response rate (ORR; primary endpoint; measured by RECIST v1.1), duration of response (DoR), disease control rate, progression-free survival (PFS; including median PFS, hazard ratio for progression or death, and 12-month PFS rate), overall survival (OS; including median OS, hazard ratio for death, and 12-month OS rate), time to progression, time to next treatment, event-free survival, duration of treatment, time to deterioration of overall health status (including hazard ratio and mean change from baseline to week 12), time to deterioration of physical functioning, quality of life (overall health status; measured by change from baseline and time to deterioration), adverse event rate (measured by CTCAE v5), rate of grade 3-4 adverse events, discontinuations due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "objective response rate (ORR; primary endpoint; measured by RECIST v1.1), duration of response (DoR), disease control rate, progression-free survival (PFS; including median PFS, hazard ratio for progression or death, and 12-month PFS rate), overall survival (OS; including median OS, hazard ratio for death, and 12-month OS rate), time to progression, time to next treatment, event-free survival, duration of treatment, time to deterioration of overall health status (including hazard ratio and mean change from baseline to week 12), time to deterioration of physical functioning, quality of life (overall health status; measured by change from baseline and time to deterioration), adverse event rate (measured by CTCAE v5), rate of grade 3-4 adverse events, discontinuations due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "objective response rate (ORR; primary endpoint; measured by RECIST v1.1), duration of response (DoR), disease control rate, progression-free survival (PFS; including median PFS, hazard ratio for progression or death, and 12-month PFS rate), overall survival (OS; including median OS, hazard ratio for death, and 12-month OS rate), time to progression, time to next treatment, event-free survival, duration of treatment, time to deterioration of overall health status (including hazard ratio and mean change from baseline to week 12), time to deterioration of physical functioning, quality of life (overall health status; measured by change from baseline and time to deterioration), adverse event rate (measured by CTCAE v5), rate of grade 3-4 adverse events, discontinuations due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "platinum doublet",
          "Outcomes": "objective response rate (ORR; primary endpoint; measured by RECIST v1.1), duration of response (DoR), disease control rate, progression-free survival (PFS; including median PFS, hazard ratio for progression or death, and 12-month PFS rate), overall survival (OS; including median OS, hazard ratio for death, and 12-month OS rate), time to progression, time to next treatment, event-free survival, duration of treatment, time to deterioration of overall health status (including hazard ratio and mean change from baseline to week 12), time to deterioration of physical functioning, quality of life (overall health status; measured by change from baseline and time to deterioration), adverse event rate (measured by CTCAE v5), rate of grade 3-4 adverse events, discontinuations due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy and tumours expressing PD-L1 with a TPS >=1%",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "objective response rate (ORR; primary endpoint; measured by RECIST v1.1), duration of response (DoR), disease control rate, progression-free survival (PFS; including median PFS, hazard ratio for progression or death, and 12-month PFS rate), overall survival (OS; including median OS, hazard ratio for death, and 12-month OS rate), time to progression, time to next treatment, event-free survival, duration of treatment, time to deterioration of overall health status (including hazard ratio and mean change from baseline to week 12), time to deterioration of physical functioning, quality of life (overall health status; measured by change from baseline and time to deterioration), adverse event rate (measured by CTCAE v5), rate of grade 3-4 adverse events, discontinuations due to adverse events, mortality-related toxicity, dropout rate, morbidity and mortality associated with clinical events"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10908
    }
  }
}